Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection

Journal of Immunology

Volumn 178, Issue 5, 2007, Pages 2699-2705

  Chu, Jang Hann J ^a   Chiang, Cern Cher S ^a   Ng, Mah Lee ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS RECEPTOR; WEST NILE VACCINE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; JAPANESE ENCEPHALITIS VIRUS; LYMPHOCYTE PROLIFERATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; VIRUS ADSORPTION; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

EID: 33847420827     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.5.2699     Document Type: Article

References (24)

1. Hayes, E. B., J. J. Sejvar, S. R. Zaki, R. S. Lanciotti, A. V. Bode, and G. L. Campbell. 2005. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 11: 1174-1179.
2. Centers for Disease Control and Prevention (CDC). West Nile virus activity-United States, January 1-December 31, 2005. MMWR Morb. Mortal. Wkly. Rep. 54: 1253-1256.
3. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375: 291-298.
4. Chu, J. J. H., R. Rajamanonmani, J. Li, R. Bhuvanakantham, J. Lescar, and M. L. Ng, 2005. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86(Pt. 2): 405-412.
5. Anderson, R. 2003. Manipulation of cell surface macromolecules by flaviviruses. Adv. Virus Res. 59: 229-274.
6. 3 integral. J. Biol. Chem. 281: 1352-1360.
7. Volk, D. E., D. W. Beasley, D. A. Kallick, M. R. Holbrook, A. D. Barrett, and D. G. Gorenstein. 2004. Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J. Biol. Chem. 279: 38755-38761.
8. Beasley, D. W., and A. D. Barrett. 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76: 13097-13100.
9. Nybakken, G. E., T. Oliphant, S. Johnson, S. Burke, M. S. Diamond, and D. H. Fremont. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437: 764-769.
10. Oliphant, T., M. Engle, G. E. Nybakken, C. Doane, S. Johnson, L. Huang, S. Gorlatov, E. Mehlhop, A. Marri, K. M. Chung, et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11: 522-530.
11. Li, L., A. D. Barrett, and D. W. Beasley. 2005. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology 335: 99-105.
12. Bhardwaj, S., M. Holbrook, R. E. Shope, A. D. T. Barrett, and S. J. Watowich. 2001. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 75: 4002-4007.
13. Chu, J. J. H., and M. L. Ng. 2004. Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J. Virol. 78: 10543-10555.
14. Lipford, G. B., M. Bauer, C. Blank, R. Reiter, H. Wagner, and K. Heeg. 1997. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27: 2340-2344.
15. Sanchez, M. D., T. C. Pierson, D. McAllister, S. L. Hanna, B. A. Puffer, L. E. Valentine, M. M. Murtadha, J. A. Hoxie, and R. W. Doms. 2005. Characterization of neutralizing antibodies to West Nile virus. Virology 336: 70-82.
16. Shi, X. J., B. Wang, C. Zhang, and M. Wang. 2006. Expressions of bovine IFN-γ and foot-and-mouth disease VP1 antigen in P. postoris and their effects on mouse immune response to FMD antigens. Vaccine 24: 82-89.
17. Ng, T., D. Hathaway, N. Jennings, D. Champ, Y. W. Chiang, and H. J. Chu. 2003. Equine vaccine for West Nile virus. Dev. Biol. 114: 221-227.
18. Gerhardt, R. 2006. West Nile virus in the United States (1999-2005). J. Am. Anim. Hosp. Assoc. 42: 170-177.
19. Minke, J. M., L. Siger, K. Karaca, L. Austgen, P. Gordy, R. Bowen, R. W. Renshaw, S. Loosmore, J. C. Audonnet, and B. Nordgren. 2004. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl. 18: 221-230.
20. Samina, I., Y. Khinich, M. Simanov, and M. Malkinson. 2005. An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application. Vaccine 23: 4955-4958.
21. Arroyo, J., C. Miller, J. Catalan, G. A. Myers, M. S. Ratterree, D. W. Trent, and T. P. Monath. 2004. ChimeriVax-West Nile virus live-attenuated vaccine: pre-clinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 278: 12497-12507.
22. Huang, C. Y., S. J. Silengo, M. C. Whiteman, and R. M. Kinney. 2005. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J. Virol. 79: 7300-7310.
23. Williams, D. T., P. W. Daniels, R. A. Lunt, L. F. Wang, K. M. Newberry, and J. S. Mackenzie. 2001. Experimental infections of pigs with Japanese encephalitis virus and closely related Australian flaviviruses: Am. J. Trop. Med. Hyg. 65: 379-387.
24. Klinman, D. M., D. Currie, I. Gursel, and D. Verthelyi. 2004. Use of CpG oligodeoxynucleotides as immune adjuvants, Immunol. Rev. 199: 201-216.